23 Feb TreeFrog Therapeutics
Daniel Castro, Chief Business Officer
Oct. 6 | 1:30pm | FLW Ballroom G
Pessac, France
(Private)
TreeFrog Therapeutics is a R&D biotech set to unlock access to cell therapies for millions of patients. The company’s unique approach to cell therapy development brings together biophysicists, cell biologists and bioproduction engineers to address the challenges of the industry – producing and differentiating cells of quality at unprecedented scale, cost-effectively. Their programs are based on their proprietary technology, C-Stem™ which encapsulates cells, allowing them to amplify and differentiate in a closed GMP-complaint system. Their lead program is developing a best-in-class iPS-derived cell therapy for Parkinson’s Disease. To realize their mission of Cell Therapy for all, TreeFrog operates a business model that includes its own programs and partnerships with leading biotech and industry players in other areas. In April 2024, TreeFrog signed a landmark licensing agreement and collaboration deal with Vertex Pharmaceuticals for the use of C -Stem™ to optimize production of Vertex’s cell therapies for Tupe 1 diabetes.
